Adult stem cell

Lineage Cell Therapeutics and AgeX Therapeutics Announce Expansion of Agreement Related to ESI Clinical-Grade Pluripotent Stem Cell Lines for Therapeutic Purposes

Retrieved on: 
Wednesday, September 9, 2020
Biotechnology, Infectious diseases, Health, Optical, Oncology, Branches of biology, Biology, Life sciences, Stem cells, Induced stem cells, Biotechnology, Cell biology, Cell culture, Stem-cell line, Adult stem cell, Embryonic stem cell, Lineage Cell Therapeutics, Inc., ESI, AgeX Therapeutics

In particular, Lineage has acquired exclusivity for the use of ESI cell lines in spinal cord injury and certain oncology indications.

Key Points: 
  • In particular, Lineage has acquired exclusivity for the use of ESI cell lines in spinal cord injury and certain oncology indications.
  • The ESI cell lines are recognized for being the first clinical-grade human pluripotent stem cell lines created under cGMP as described in the publication Cell Stem Cell (2007;1:490-4).
  • These cell lines are listed on the NIH Stem Cell Registry and are among the best characterized and documented stem cell lines available globally.
  • These ESI cell lines are extensively characterized and most of the lines have documented and publicly available genomic sequences.

New Report Begins a New Era of Stem Cell Science and Medicine: Stem Cell Biotechnology Company Asymmetrex Tells How It Counts Therapeutic Tissue Stem Cells

Retrieved on: 
Tuesday, September 1, 2020
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Induced stem cells, Cell biology, Developmental biology, Adult stem cell, Stem-cell line

The stem cell counting algorithms are specific for different types of tissue stem cells.

Key Points: 
  • The stem cell counting algorithms are specific for different types of tissue stem cells.
  • So, the algorithms defined for blood stem cells are distinct from the algorithms for liver stem cells, or lung stem cells.
  • Then and now, he says that he believes, "Now that the tissue stem cell counting algorithms are available, everything will change" in stem cell science and medicine.
  • Such information is a game changer for accelerating progress in stem cell science and stem cell medicine, including improving treatments like gene therapy whose success depends on targeting tissue stem cells.

BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Corporate and R&D Update

Retrieved on: 
Monday, July 27, 2020
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Mesenchymal stem cell, Adult stem cell, Induced stem cells, Stem-cell therapy

MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.

Key Points: 
  • MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.
  • BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS).
  • BrainStorm Cell Therapeutics Inc.is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.
  • Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

R3 International Offering New Program for Stem Cell Therapy for Liver Failure in Mexico

Retrieved on: 
Monday, June 29, 2020
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Emerging technologies, Life extension, Stem-cell therapy, Cell therapy, Therapy, Adult stem cell

SAN DIEGO, June 29, 2020 /PRNewswire-PRWeb/ -- R3 International is now offering a new program for stem cell therapy for liver failure in Mexico.

Key Points: 
  • SAN DIEGO, June 29, 2020 /PRNewswire-PRWeb/ -- R3 International is now offering a new program for stem cell therapy for liver failure in Mexico.
  • Stem cell therapy has been shown in several studies to produce beneficial results for liver failure.
  • Each treatment provides up to 50 million stem cells at a time, with the treatment occurring at the stem cell therapy clinic in Tijuana Mexico.
  • To date, hundreds of patients have received stem cell therapy in Mexico with R3 for a variety of conditions.

Worldwide Stem Cell Therapy Industry to 2027 - Growth in the Global Healthcare Market Presents Opportunities

Retrieved on: 
Thursday, June 18, 2020
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Induced stem cells, Emerging technologies, Developmental biology, Stem-cell therapy, Adult stem cell, Embryonic stem cell, Induced pluripotent stem cell

The increasing awareness related to the stem cells therapy in effective disease management and growing demand for regenerative medicines are the key factor driving the stem cell therapy market.

Key Points: 
  • The increasing awareness related to the stem cells therapy in effective disease management and growing demand for regenerative medicines are the key factor driving the stem cell therapy market.
  • However, high cost related of the stem cell therapy limits the growth of the market.
  • Based on type, the market has been segmented into adult stem cell therapy, induced pluripotent stem cell therapy, embryonic stem cell therapy, and others.
  • The adult stem cell therapy held the largest share of the market in 2019; however, induced pluripotent stem cell therapy is estimated to register the highest CAGR in the market during the forecast period.

Stem Cell Therapy Market to 2027 - Global Analysis and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Monday, June 15, 2020
Health, Stem cells, Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Induced stem cells, Cell biology, Developmental biology, Stem-cell therapy, Adult stem cell, Embryonic stem cell, Induced pluripotent stem cell

The "Stem Cell Therapy Market to 2027 - Global Analysis and Forecasts by Type; Treatment; Application; End User, and Geography" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Stem Cell Therapy Market to 2027 - Global Analysis and Forecasts by Type; Treatment; Application; End User, and Geography" report has been added to ResearchAndMarkets.com's offering.
  • The increasing awareness related to the stem cells therapy in effective disease management and growing demand for regenerative medicines are the key factor driving the stem cell therapy market.
  • Based on type, the market has been segmented into adult stem cell therapy, induced pluripotent stem cell therapy, embryonic stem cell therapy, and others.
  • The adult stem cell therapy held the largest share of the market in 2019; however, induced pluripotent stem cell therapy is estimated to register the highest CAGR in the market during the forecast period.

Insights into North America's Biobanks Market 2020, Featuring Key Player Profiles Including Atlanta Biologicals Inc., BioLifeSolutions Inc. and Thermo Fisher Scientific Inc.

Retrieved on: 
Friday, May 22, 2020
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cloning, Induced stem cells, Emerging technologies, Umbilical cord, Regenerative medicine, Stem-cell therapy, Adult stem cell

Stem cell practices are on the rise and are contributing to the development of new solutions for various diseases.

Key Points: 
  • Stem cell practices are on the rise and are contributing to the development of new solutions for various diseases.
  • Several advancements have been made in regenerative medicine through stem cell technology over the past decade.
  • Thus, it has become one of the vital treatment methods for diseases, such as Alzheimer's, diabetes, cancer, and rare genetic diseases.
  • In order to benefit from the existing therapies, umbilical cord cells and other stem cells are preserved in Biobanks.

Creative Medical Technology Holdings is Granted Patent on Mesenchymal Stem Cells for Female Infertility Pending Quayle Action

Retrieved on: 
Monday, April 20, 2020
Branches of biology, Biology, Life sciences, Biotechnology, Women's health, Stem cells, Fertility medicine, Developmental biology, Ovary, Infertility, Premature ovarian failure, Adult stem cell

PHOENIX, April 20, 2020 /PRNewswire/ --Creative Medical Technology Holdings Inc. (OTC-CELZ) announced today receipt of a Quayle Action on its patent application #15/652213 entitled Methods for Treatment of Premature Ovarian Failure and Ovarian Aging using Regenerative Cells.

Key Points: 
  • PHOENIX, April 20, 2020 /PRNewswire/ --Creative Medical Technology Holdings Inc. (OTC-CELZ) announced today receipt of a Quayle Action on its patent application #15/652213 entitled Methods for Treatment of Premature Ovarian Failure and Ovarian Aging using Regenerative Cells.
  • The patent covers use of mesenchymal stem cells, a class of adult stem cells, for use in treatment of ovarian failure and ovarian aging.
  • A "Quayle Action" is issued when there are minor issues to be resolved in a patent application that is otherwise in condition forallowance.
  • 2017 Jun 15;9:441-447
    View original content to download multimedia: http://www.prnewswire.com/news-releases/creative-medical-technology-hold...
    SOURCE Creative Medical Technology Holdings, Inc.

Stem Cell Therapy Market to 2027 - Global Analysis and Forecasts by Type; Treatment; Application; End User, and Geography

Retrieved on: 
Wednesday, April 15, 2020
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Induced stem cells, Cell biology, Emerging technologies, Stem-cell therapy, Adult stem cell, Embryonic stem cell, Induced pluripotent stem cell

The increasing awareness related to the stem cells therapy in effective disease management and growing demand for regenerative medicines are the key factor driving the stem cell therapy market.

Key Points: 
  • The increasing awareness related to the stem cells therapy in effective disease management and growing demand for regenerative medicines are the key factor driving the stem cell therapy market.
  • However, high cost related of the stem cell therapy limits the growth of the market.
  • The global stem cell therapy market has been segmented on the basis of type, treatment, application type, and end user.Based on type, the market has been segmented into adult stem cell therapy, induced pluripotent stem cell therapy, embryonic stem cell therapy, and others.
  • The adult stem cell therapy held the largest share of the market in 2019; however, induced pluripotent stem cell therapy is estimated to register the highest CAGR in the market during the forecast period.Based on treatment, the stem cell therapy market has been segmented into allogeneic and autologous.

BrainStorm Awarded $1.5 Million Non-Dilutive Grant for 2020 by the Israel Innovation Authority

Retrieved on: 
Friday, April 3, 2020
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Developmental biology, Induced stem cells, Cell biology, Mesenchymal stem cell, Cellular differentiation, Adult stem cell, Petach

NEW YORK and PETACH TIKVAH, Israel, April 03, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that its wholly-owned subsidiary, Brainstorm Cell Therapeutics Ltd., has been awarded a new grant of approximately $1.5 million by the Israel Innovation Authority (IIA).

Key Points: 
  • NEW YORK and PETACH TIKVAH, Israel, April 03, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that its wholly-owned subsidiary, Brainstorm Cell Therapeutics Ltd., has been awarded a new grant of approximately $1.5 million by the Israel Innovation Authority (IIA).
  • BrainStorm's CEO Chaim Lebovits, commented, "The Israel Innovation Authority's support of our programs provides further validation for the potential of our treatments to help patients suffering from neurodegenerative disorders.
  • The IIA has supported BrainStorm Cell Therapeutics Ltd. since 2007, providing grants totaling approximately 11.4 million USD in support of the development of NurOwn and other projects.
  • MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.